Last Updated on January 4, 2024 by The Health Master
The US Food and Drug Administration (USFDA) has issued Form 483 to Cipla’s manufacturing facility in Pithampur, Madhya Pradesh.
The USFDA has censured the drug maker due to unclean equipment and lack of data.
This particular facility also came under the FDA once in 2018.
USFDA issues Form 483 with 6 observations to Sun Pharma
USFDA issues Form 483 for 4 observations to Zydus
USFDA completes inspection at Stride Pharma with zero observation
USFDA issues Form 483 for 6 observations to Jubilant Pharmova
USFDA issues Form 483 for 3 observations to Aurobindo Pharma
USFDA completes inspection of Casper Pharma with Zero Observations
Nicotine replacement therapy may become part of Essential Medicines List
Drug recall: Glenmark, Strides Pharma, Cipla recalled these drugs
DCGI approves olaparib as monotherapy for high-risk early breast cancer
USFDA issues Form 483 with 6 observations to Sun Pharma
Anti-dumping duty recommended on Ofloxacin & its intermediates imported from China
HP: Pharma units, Wholesalers, Chemist Shops under scanner of Anti Narcotic…
Dr VG Somani to continue as DCGI for next three months
Drug alert: 53 out of 1337 samples declared as NSQ in July 2022
20 Blood Banks fined ₹2.3cr for overcharging
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
